iShares
®
U.S.
Medical
Devices
ETF
Schedule
of
Investments
(unaudited)
June
30,
2024
(Percentages
shown
are
based
on
Net
Assets)
1
Schedule
of
Investments
Security
Shares
Value
a
Common
Stocks
Health
Care
Equipment
—
99
.8
%
Abbott
Laboratories
........................
7,905,571
$
821,467,883
Alphatec
Holdings,
Inc.
(a)
(b)
....................
670,912
7,011,030
Artivion,
Inc.
(a)
(b)
...........................
267,818
6,869,532
AtriCure,
Inc.
(a)
(b)
..........................
326,827
7,441,851
Axogen,
Inc.
(a)
............................
295,228
2,137,451
Axonics,
Inc.
(a)
............................
344,630
23,169,475
Baxter
International,
Inc.
.....................
3,442,307
115,145,169
Becton
Dickinson
&
Co.
.....................
988,163
230,943,575
Boston
Scientific
Corp.
(a)
.....................
3,400,438
261,867,730
CONMED
Corp.
...........................
208,064
14,422,996
Dexcom,
Inc.
(a)
...........................
1,972,870
223,684,001
Edwards
Lifesciences
Corp.
(a)
(b)
................
2,634,392
243,338,789
Enovis
Corp.
(a)
(b)
...........................
337,173
15,240,220
Envista
Holdings
Corp.
(a)
(b)
....................
1,160,939
19,306,416
GE
HealthCare
Technologies,
Inc.
..............
2,867,651
223,447,366
Glaukos
Corp.
(a)
...........................
340,249
40,268,469
Globus
Medical,
Inc.
,
Class
A
(a)
(b)
...............
760,823
52,108,767
Hologic,
Inc.
(a)
............................
1,576,502
117,055,274
IDEXX
Laboratories,
Inc.
(a)
(b)
..................
449,602
219,046,094
Inari
Medical,
Inc.
(a)
(b)
.......................
349,537
16,830,207
Inspire
Medical
Systems,
Inc.
(a)
(b)
...............
200,701
26,859,815
Insulet
Corp.
(a)
............................
473,132
95,478,038
Integer
Holdings
Corp.
(a)
(b)
....................
226,323
26,205,940
Integra
LifeSciences
Holdings
Corp.
(a)
(b)
...........
463,116
13,495,200
Intuitive
Surgical,
Inc.
(a)
(b)
.....................
1,611,926
717,065,281
iRhythm
Technologies,
Inc.
(a)
(b)
.................
210,120
22,617,317
LeMaitre
Vascular,
Inc.
......................
134,946
11,103,357
LivaNova
PLC
(a)
...........................
365,810
20,053,704
Masimo
Corp.
(a)
...........................
301,227
37,936,528
Medtronic
PLC
...........................
2,811,879
221,322,996
Nevro
Corp.
(a)
(b)
...........................
248,108
2,089,069
Novocure
Ltd.
(a)
...........................
661,509
11,331,649
Omnicell,
Inc.
(a)
...........................
310,215
8,397,520
Orthofix
Medical,
Inc.
(a)
......................
253,511
3,361,556
Paragon
28,
Inc.
(a)
(b)
........................
243,336
1,664,418
Penumbra,
Inc.
(a)
(b)
.........................
261,870
47,128,744
Security
Shares
Value
a
Health
Care
Equipment
(continued)
PROCEPT
BioRobotics
Corp.
(a)
(b)
...............
302,226
$
18,462,986
QuidelOrtho
Corp.
(a)
(b)
.......................
334,786
11,121,591
ResMed,
Inc.
............................
992,386
189,962,528
Senseonics
Holdings,
Inc.
(a)
...................
143,161
57,121
SI-BONE,
Inc.
(a)
(b)
..........................
253,290
3,275,040
Silk
Road
Medical,
Inc.
(a)
.....................
266,449
7,204,781
STERIS
PLC
.............................
667,512
146,545,584
Stryker
Corp.
............................
1,540,759
524,243,250
Surmodics,
Inc.
(a)
..........................
96,324
4,049,461
Tandem
Diabetes
Care,
Inc.
(a)
(b)
................
436,314
17,579,091
Teleflex,
Inc.
.............................
318,192
66,925,323
TransMedics
Group,
Inc.
(a)
(b)
...................
222,492
33,511,745
Treace
Medical
Concepts,
Inc.
(a)
(b)
...............
293,221
1,949,920
Varex
Imaging
Corp.
(a)
......................
276,291
4,069,766
Zimmer
Biomet
Holdings,
Inc.
.................
1,389,724
150,826,746
a
Total
Long-Term Investments
— 99.8%
(Cost:
$
5,298,558,278
)
...............................
5,106,698,360
a
Short-Term
Securities
Money
Market
Funds
—
2
.2
%
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
,
5.48
%
(c)
(d)
(e)
............................
106,246,309
106,278,182
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares
,
5.28
%
(c)
(d)
.............................
7,522,031
7,522,031
a
Total
Short-Term
Securities — 2.2%
(Cost:
$
113,767,002
)
................................
113,800,213
Total
Investments
—
102.0%
(Cost:
$
5,412,325,280
)
...............................
5,220,498,573
Liabilities
in
Excess
of
Other
Assets
—
(
2
.0
)
%
...............
(
103,005,526
)
Net
Assets
—
100.0%
.................................
$
5,117,493,047
(a)
Non-income
producing
security.
(b)
All
or
a
portion
of
this
security
is
on
loan.
(c)
Affiliate
of
the
Fund.
(d)
Annualized
7-day
yield
as
of
period
end.
(e)
All
or
a
portion
of
this
security
was
purchased
with
the
cash
collateral
from
loaned
securities.
Affiliates
Investments
in
issuers
considered
to
be
affiliate(s)
of
the
Fund
during
the
period
ended
June
30,
2024
for
purposes
of
Section
2(a)(3)
of
the
Investment
Company
Act
of
1940,
as
amended,
were
as
follows:
Affiliated
Issuer
Value
at
03/31/24
Purchases
at
Cost
Proceeds
from
Sale
Net
Realized
Gain
(Loss)
Change
in
Unrealized
Appreciation
(Depreciation)
Value
at
06/30/24
Shares
Held
at
06/30/24
Income
Capital
Gain
Distributions
from
Underlying
Funds
BlackRock
Cash
Funds:
Institutional,
SL
Agency
Shares
$
119,537,217
$
—
$
(
13,255,080
)
(a)
$
1,134
$
(
5,089
)
$
106,278,182
106,246,309
$
61,956
(b)
$
—
BlackRock
Cash
Funds:
Treasury,
SL
Agency
Shares
......
6,174,241
1,347,790
(a)
—
—
—
7,522,031
7,522,031
102,782
—
$
1,134
$
(
5,089
)
$
113,800,213
$
164,738
$
—
Schedule
of
Investments
(unaudited)
(continued)
June
30,
2024
iShares
®
U.S.
Medical
Devices
ETF
2
Derivative
Financial
Instruments
Outstanding
as
of
Period
End
Fair
Value
Hierarchy
as
of
Period
End
Various
inputs
are
used
in
determining
the
fair
value
of
financial
instruments.
These
inputs
to
valuation
techniques
are
categorized
into
a
fair
value
hierarchy
consisting
of
three
broad
levels
for
financial
reporting
purposes
as
follows:
Level
1
–
Unadjusted
price
quotations
in
active
markets/exchanges
for
identical
assets
or
liabilities
that
the
Fund
has
the
ability
to
access;
Level
2
–
Other
observable
inputs
(including,
but
not
limited
to,
quoted
prices
for
similar
assets
or
liabilities
in
markets
that
are
active,
quoted
prices
for
identical
or
similar
assets
or
liabilities
in
markets
that
are
not
active,
inputs
other
than
quoted
prices
that
are
observable
for
the
assets
or
liabilities
(such
as
interest
rates,
yield
curves,
volatilities,
prepayment
speeds,
loss
severities,
credit
risks
and
default
rates)
or
other
market–corroborated
inputs);
and
Level
3
–
Unobservable
inputs
based
on
the
best
information
available
in
the
circumstances,
to
the
extent
observable
inputs
are
not
available
(including
the
Valuation
Committee’s
assumptions
used
in
determining
the
fair
value
of
financial
instruments).
The
hierarchy
gives
the
highest
priority
to
unadjusted
quoted
prices
in
active
markets
for
identical
assets
or
liabilities
(Level
1
measurements)
and
the
lowest
priority
to
unobservable
inputs
(Level
3
measurements).
Accordingly,
the
degree
of
judgment
exercised
in
determining
fair
value
is
greatest
for
instruments
categorized
in
Level
3.
The
inputs
used
to
measure
fair
value
may
fall
into
different
levels
of
the
fair
value
hierarchy.
In
such
cases,
for
disclosure
purposes,
the
fair
value
hierarchy
classification
is
determined
based
on
the
lowest
level
input
that
is
significant
to
the
fair
value
measurement
in
its
entirety.
Investments
classified
within
Level
3
have
significant
unobservable
inputs
used
by
the
Valuation
Committee
in
determining
the
price
for
Fair
Valued
Investments.
Level
3
investments
include
equity
or
debt
issued
by
privately
held
companies
or
funds.
There
may
not
be
a
secondary
market,
and/or
there
are
a
limited
number
of
investors.
The
categorization
of
a
value
determined
for
financial
instruments
is
based
on
the
pricing
transparency
of
the
financial
instruments
and
is
not
necessarily
an
indication
of
the
risks
associated
with
investing
in
those
securities.
For
information
about
the
Fund’s
policy
regarding
valuation
of
financial
instruments,
refer
to
its
most
recent
financial
statements.
The
following
table
summarizes
the
Fund’s
financial
instruments
categorized
in
the
fair
value
hierarchy.
The
breakdown
of
the
Fund’s
financial
instruments
into
major
categories
is
disclosed
in
the
Schedule
of
Investments
above.
(a)
Represents
net
amount
purchased
(sold).
(b)
All
or
a
portion
represents
securities
lending
income
earned
from
the
reinvestment
of
cash
collateral
from
loaned
securities,
net
of
fees
and
collateral
investment
expenses,
and
other
payments
to
and
from
borrowers
of
securities.
Futures
Contracts
Description
Number
of
Contracts
Expiration
Date
Notional
Amount
(000)
Value/
Unrealized
Appreciation
(Depreciation)
Long
Contracts
E-Mini
Health
Care
Select
Sector
Index
......................................................
52
09/20/24
$
7,745
$
(
9,137
)
E-Mini
Technology
Select
Sector
Index
......................................................
11
09/20/24
2,539
(
7,357
)
$
(
16,494
)
Level
1
Level
2
Level
3
Total
Assets
Investments
Long-Term
Investments
Common
Stocks
.........................................
$
5,106,698,360
$
—
$
—
$
5,106,698,360
Short-Term
Securities
Money
Market
Funds
......................................
113,800,213
—
—
113,800,213
$
5,220,498,573
$
—
$
—
$
5,220,498,573
Derivative
Financial
Instruments
(a)
Liabilities
Equity
Contracts
...........................................
$
(
16,494
)
$
—
$
—
$
(
16,494
)
a
(a)
Derivative
financial
instruments
are
futures
contracts.
Futures
contracts
are
valued
at
the
unrealized
appreciation
(depreciation)
on
the
instrument.